SCHEMBL4250052

SCHEMBL4250052

COc1ccc(NCc2ccccc2)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.59
MEN1 O00255 3/20 0.59
HDAC1 Q13547 1/20 0.58
PDGFRB P09619 1/20 0.55
PDGFRA P16234 1/20 0.55
PABPC1 P11940 3/20 0.53
LMNA P02545 4/20 0.51
NPC1 O15118 3/20 0.51
PKM P14618 1/20 0.51
HTT P42858 4/20 0.50
PIK3CA P42336 1/20 0.50
NPSR1 Q6W5P4 3/20 0.49
ALDH1A1 P00352 3/20 0.49
POLB P06746 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
RAB9A P51151 3/20 0.48
S1PR2 O95136 2/20 0.48
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25638644 0.86 NPC1 (0.50) KMT2AMEN1HDAC1PDGFRBPDGFRA
SCHEMBL1846278 0.82 HDAC1 (0.51) KMT2AMEN1HDAC1LMNANPC1
SCHEMBL28487636 0.79 HDAC1 (0.60) KMT2AMEN1HDAC1PABPC1LMNA
SCHEMBL9650898 0.79 KMT2A (0.63) KMT2AMEN1HDAC1PABPC1LMNA
SCHEMBL14808808 0.78 HTT (0.50) KMT2AMEN1HDAC1PDGFRBPDGFRA
SCHEMBL16601601 0.78 HTT (0.59) HDAC1PDGFRBPDGFRALMNAHTT
SCHEMBL8349276 0.78 KMT2A (0.53) KMT2AMEN1PABPC1LMNANPC1
SCHEMBL22531105 0.77 PKM (0.57) KMT2AHDAC1PKMHTTNPSR1
SCHEMBL7013357 0.76 NOS2 (0.53) KMT2AMEN1PDGFRBPDGFRALMNA
SCHEMBL14127745 0.76 KMT2A (0.54) KMT2AMEN1PABPC1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090082357-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2009-03-26 US disclosed
EP-1991227-A2 PROLYL HYDROXYLASE INHIBITORS SmithKline Beecham Corporation (US) 2008-11-19 EP disclosed
WO-2007103905-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO disclosed
US-20070213335-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082357-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 KMT2A 444/4885MEN1 3087/4885HDAC1 686/4885
US-20070213335-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 KMT2A 444/4885MEN1 3087/4885HDAC1 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.